Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,657 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission.
Yano S, Yokoyama H, Yanada M, Mori J, Aoki J, Ohashi K, Kanomori H, Ozawa Y, Sawa M, Nakamae H, Eto T, Ohta S, Tanaka J, Ichinohe T, Atsuta Y, Takami A. Yano S, et al. Among authors: ozawa y. Bone Marrow Transplant. 2019 Dec;54(12):2004-2012. doi: 10.1038/s41409-019-0571-8. Epub 2019 May 31. Bone Marrow Transplant. 2019. PMID: 31152148
Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil.
Terakura S, Wake A, Inamoto Y, Murata M, Sakai R, Yamaguchi T, Takahashi S, Uchida N, Onishi Y, Ohashi K, Ozawa Y, Kanamori H, Yamaguchi H, Fukuda T, Ichinohe T, Takanashi M, Atsuta Y, Teshima T. Terakura S, et al. Among authors: ozawa y. Bone Marrow Transplant. 2017 Mar;52(3):423-430. doi: 10.1038/bmt.2016.255. Epub 2016 Dec 12. Bone Marrow Transplant. 2017. PMID: 27941766
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study.
Yanada M, Kurosawa S, Kobayashi T, Ozawa Y, Kanamori H, Kobayashi N, Sawa M, Nakamae H, Uchida N, Hashimoto H, Fukuda T, Hirokawa M, Atsuta Y, Yano S. Yanada M, et al. Among authors: ozawa y. Bone Marrow Transplant. 2017 Jun;52(6):818-824. doi: 10.1038/bmt.2016.358. Epub 2017 Jan 23. Bone Marrow Transplant. 2017. PMID: 28112749 Clinical Trial.
Decision analysis for donor selection in stem cell transplantation-HLA-8/8 allele-matched unrelated donor vs HLA-1 AG mismatched related donor.
Kanda J, Fuji S, Kato S, Takami A, Tanaka J, Miyamura K, Ohashi K, Fukuda T, Ozawa Y, Kanamori H, Eto T, Kobayashi N, Iwato K, Morishima Y, Sakamaki H, Atsuta Y, Kanda Y; HLA Working Group; Donor/Source Working Group; Adult AML Working Group; Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Kanda J, et al. Among authors: ozawa y. Blood Cancer J. 2014 Dec 5;4(12):e263. doi: 10.1038/bcj.2014.85. Blood Cancer J. 2014. PMID: 25479570 Free PMC article. Clinical Trial.
Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation.
Kanda J, Morishima Y, Terakura S, Wake A, Uchida N, Takahashi S, Ono Y, Onishi Y, Kanamori H, Aotsuka N, Ozawa Y, Ogawa H, Sakura T, Ohashi K, Ichinohe T, Kato K, Atsuta Y, Teshima T, Murata M. Kanda J, et al. Among authors: ozawa y. Leukemia. 2017 Mar;31(3):663-668. doi: 10.1038/leu.2016.288. Epub 2016 Oct 17. Leukemia. 2017. PMID: 27748373
Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation.
Kawamura K, Kanda J, Fuji S, Murata M, Ikegame K, Yoshioka K, Fukuda T, Ozawa Y, Uchida N, Iwato K, Sakura T, Hidaka M, Hashimoto H, Ichinohe T, Atsuta Y, Kanda Y. Kawamura K, et al. Among authors: ozawa y. Bone Marrow Transplant. 2017 Oct;52(10):1390-1398. doi: 10.1038/bmt.2017.153. Epub 2017 Jul 17. Bone Marrow Transplant. 2017. PMID: 28714944 Clinical Trial.
Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged ⩾55 years with hematological malignancies.
Miyao K, Sawa M, Kuwatsuka Y, Ozawa Y, Kato T, Kohno A, Sao H, Nishida T, Iida H, Naito K, Tsurumi H, Taji H, Mizuta S, Kusumoto S, Nakase K, Morishita Y, Kawashima N, Miyamura K, Murata M; Nagoya Blood and Marrow Transplantation Group. Miyao K, et al. Among authors: ozawa y. Bone Marrow Transplant. 2016 Jan;51(1):157-60. doi: 10.1038/bmt.2015.235. Epub 2015 Oct 5. Bone Marrow Transplant. 2016. PMID: 26437064 No abstract available.
Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy.
Kawashima N, Inamoto Y, Sato T, Nakashima M, Kagaya Y, Watakabe K, Seto A, Fukushima N, Kurahashi S, Ozawa Y, Miyamura K. Kawashima N, et al. Among authors: ozawa y. Bone Marrow Transplant. 2016 Jun;51(6):869-71. doi: 10.1038/bmt.2016.15. Epub 2016 Feb 15. Bone Marrow Transplant. 2016. PMID: 26878661 No abstract available.
Clinical significance of hemophagocytosis in BM clot sections during the peri-engraftment period following allogeneic hematopoietic SCT.
Imahashi N, Inamoto Y, Ito M, Koyama D, Goto T, Onodera K, Seto A, Watanabe K, Imahashi M, Nishiwaki S, Tsukamoto S, Yasuda T, Ozawa Y, Miyamura K. Imahashi N, et al. Among authors: ozawa y. Bone Marrow Transplant. 2012 Mar;47(3):387-94. doi: 10.1038/bmt.2011.95. Epub 2011 Apr 18. Bone Marrow Transplant. 2012. PMID: 21499316
1,657 results